^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ER negative

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    Entrez ID:
    2099
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    3d
    The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial. (PubMed, J Natl Cancer Inst)
    Pertuzumab numerically improved IDFS in all subgroups, greatest in HER2 FISH-low/ER-positive tumors. These exploratory findings are hypothesis-generating and support prospective validation of biomarker-guided strategies.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 amplification • HER-2 expression • ER negative
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    4d
    Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention (clinicaltrials.gov)
    P=N/A, N=80, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2026 --> Feb 2027 | Trial primary completion date: Jun 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative
    4d
    QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Qibeian (iparomlimab/tuvonralimab)
    5d
    FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov)
    P2, N=120, Recruiting, Fudan University
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    everolimus • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020)
    6d
    Endogenous and environmental factors that induce DNA replication defects and genomic instability in ER-negative heterozygous BRCA1 cells. (PubMed, Sci Rep)
    Approximately 70% of BRCA1-associated breast cancers are triple negative (TNBC; progesterone (PR), HER2, estrogen receptor (ER)-negative), which were reported to develop from ER/PR-negative luminal progenitor cells...In summary, these results reveal that alterations in estrogen metabolism caused by environmental or endogenous factors are genotoxic for ER-negative BRCA1mut/+ mammary cells. And our results also show that the dietary compound I3C can prevent estrogen-induced DNA damage, and suggest that I3C can be a potential cancer-preventive therapeutic agent for BRCA1 carriers.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset)
    |
    BRCA1 mutation • ER negative
    7d
    A Five-Year Retrospective Analysis of Neoadjuvant Therapy in Early-Stage Breast Cancer: Subtype Outcomes and Imaging Concordance. (PubMed, Breast J)
    NST was effective across aggressive subtypes, with pCR rates comparable to those observed in clinical trials. In summary, our results highlighted the contributions of functional imaging with PET/CT and MRI to staging, treatment response assessments and surgical planning in real-world clinical practice.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive
    7d
    Artificial intelligence-assisted FTIR spectroscopy for hormone receptor subtyping in formalin-fixed breast Cancer tissues. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc)
    AI-enhanced ATR-FTIR spectroscopy demonstrates high diagnostic potential for hormone receptor subtyping in FFPE tissues. As a label-free, scalable platform, it offers a promising alternative to IHC, particularly in resource-constrained environments. These findings establish the technical feasibility of this approach and warrant further validation in multicenter clinical cohorts.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • ER negative
    9d
    Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours (clinicaltrials.gov)
    P3, N=11000, Active, not recruiting, University College, London | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    aspirin
    11d
    Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor Expression. (PubMed, Curr Oncol)
    USC is a biologically heterogeneous disease, and its treatment should be guided by its molecular profile. ER expression identifies a subset of patients with improved DFS, suggesting potential prognostic relevance in this high-risk histology.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PGR (Progesterone receptor)
    |
    TP53 mutation • ER positive • HER-2 amplification • ER negative
    13d
    Estrogen Metabolism-Related Lifestyle Score and Risk of Postmenopausal Breast, Endometrial, and Ovarian Cancers: Findings from Two Large Prospective Cohort Studies. (PubMed, Cancer Prev Res (Phila))
    We showed that lifestyle patterns increasing the 2-OH EM/parent E ratio were associated with lower postmenopausal breast and endometrial cancer risk. Our findings suggest that targeted lifestyle modifications may benefit postmenopausal women with a low 2-OH EM/parent E ratio.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • ER negative
    14d
    Complete NUB1 depletion in ER - negative breast cancer progression in paired primary-metastatic cases: a case series. (PubMed, J Med Case Rep)
    Loss of NEDD8 ultimate buster 1 in metastases may signal a transition from hypoxia-driven nuclear localization to unchecked metastatic progression. These findings highlight NEDD8 ultimate buster 1 as a potential prognostic marker and therapeutic stratifier, warranting larger studies to confirm its mechanistic and clinical relevance.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative • ER negative
    14d
    A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=43, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin